Table 1.
Non-randomized prospective series assessing, with a very long follow-up (>5 years), biochemical outcome of localized prostate cancer treated with brachytherapy (BT).
| NCCN Risk Groups (n) | bRFS (%) [Time Point] | ||||
|---|---|---|---|---|---|
| Authors | LR | FIR | FU (y) | LR | FIR |
| Sylvester 2011 [44] | 128 | 36 | 11.7 | 86 [15y] | 80 [15y] |
| Morris 2013 [45] | 586 | 419 | 7.5 | 94 [10y] | |
| Kittel 2015 [46] | 1219 | 592 | 6.8 | 87 [10y] | 79 [10y] |
| Cosset 2016 [47] | 452 | 223 | 11.0 | 87 [10y] | 71 [10y] |
| Wilson 2016 [48] | 90 | 84 | 7.8 | 96 [10y] | 91 [10y] |
| Langley 2017 [49] | 316 | 220 | 8.9 | 95 [10y] | 90 [10y] |
| Prada 2018 [50] | 229 | 41 | 9.2 | 94 [15y] | 76 [15y] |
| Jacobsen 2018 [51] | 206 | 265 | 6.6 | 90 [10y] | 75 [10y] |
| Winoker 2019 [52] | 241 | 89 | 9.9 | 93 [15y] | 83 [15y] |
| Vuolukka 2019 [53] | 142 | 85 | 11.4 | 85 [10y] | 72 [10y] |
| Lazarev 2019 [54] | 370 | 170 | 12.5 | 86 [17y] | 80 [17y] |
LR = low risk; FIR = favorable intermediate risk; FU = median follow-up; bRFS = biochemical recurrence-free survival.